VivoSeq
Oncology

Metastatic Hormone-Sensitive Prostate Cancer (mhspc)

5

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) is an early-stage landscape with 5 programs across 5 companies. The most active players are Bayer, Amgen, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

1 program

Phase 2Novartis logo

Novartis

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Recruiting4 · 100%

Clinical Trials

Trial Activity

A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Recruiting·Amgen logoAmgen·Phase 1·NCT07140900·60 enrolled
An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer
Recruiting·Bayer logoBayer·N/A·NCT06661122·100 enrolled
A Phase II Randomized, Decentralized, De-escalation Study in Patients With Metastatic Hormone-Sensitive Prostate Cancer Achieving Optimal PSA Response (OPTIMAS)
Recruiting·UUniversity of Utah·Phase 2·NCT07216248·160 enrolled
TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer
Recruiting·Novartis logoNovartis·Preclinical·NCT07190300·181 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)